# CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors

> **NCT00949624** · PHASE1 · COMPLETED · sponsor: **Arog Pharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** CP-868,596
- **DRUG:** Docetaxel
- **DRUG:** CP-868,596
- **DRUG:** Docetaxel
- **DRUG:** CP-868,596
- **DRUG:** Docetaxel
- **DRUG:** CP-868,596
- **DRUG:** AG-013736
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00949624
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949624, "CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00949624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*